Your session is about to expire
← Back to Search
Blood Pressure Intervention for Rheumatoid Arthritis
Study Summary
This trial will study ways to reduce high risk of CAD & premature death in Black RA patients by improving hypertension care.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 18 years old.I do not have rheumatoid arthritis or high blood pressure.I am unable to understand or agree to the study because of cognitive issues.You identify yourself as 'Black' or 'African American'.I am 18 years old or older.You get medical care from both primary care and rheumatology departments at Duke Health System.My high blood pressure is not under control.I have a history of rheumatoid arthritis.
- Group 1: Blood pressure intervention arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does enrollment for this experiment remain open?
"This medical trial, which was first published on March 20th of 2023, is not currently accepting participants. Even so, the website clinicaltrials.gov showcases 1134 other trials actively enrolling patients at this moment in time."
What outcomes is this clinical trial seeking to obtain?
"This 6-month trial aims to gauge the feasibility of this intervention based on participant survey responses. Secondary objectives include monitoring rheumatoid arthritis disease activity with RAPID3 scores, measuring medication use for hypertension and RA over a biweekly period, and assessing anti-hypertensive drug adherence every 2 weeks during the study duration."
Share this study with friends
Copy Link
Messenger